Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06333015 · ClinicalTrials.gov registry record · NA
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
A NA study of Cataract, sponsored by Bausch & Lomb Incorporated.
- Active
- Registry status
- NA
- Development phase
- 304
- Enrollment target
- 16
- Study locations
NCT06333015: Active NA study of Cataract, sponsored by Bausch & Lomb Incorporated.
NCT06333015 is a NA study of Cataract that is active but no longer recruiting, run by Bausch & Lomb Incorporated. The registered enrollment target is 304 participants, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (35% higher). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06333015, a NA study of Cataract, is active but no longer recruiting, sponsored by Bausch & Lomb Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 304 participants
- Enrollment target
- 16
- Study locations
Study Summary
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
Primary Outcome
Monocular photopic DCIVA (logMAR) will be measured at 66 cm in the first implanted eye.
Conditions Studied
Interventions
- DEVICE enVista Beyond EY (EDF) IOL
- DEVICE enVista MX60E monofocal IOL
Study Locations (16)
Texas
- Site 103 - Dallas
- Site 117 - San Antonio
- Site 112 - San Antonio
- Site 115 - Sugar Land
Minnesota
- Site 116 - Alexandria
- Site 107 - Bloomington
Alabama
- Site 119 - Dothan
California
- Site 108 - Northridge
Nebraska
- Site 101 - Omaha
Nevada
- Site 109 - Las Vegas
New York
- Site 113 - Garden City
North Dakota
- Site 118 - West Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2026-07 |
| Phase | NA |
What the registry record for NCT06333015 still lists
NCT06333015 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (35% higher).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which enVista Beyond EY (EDF) IOL is the first listed.
NCT06333015 lists 16 locations in 12 states (Texas, Minnesota, Alabama).
Frequently Asked Questions
What is clinical trial NCT06333015 about?
NCT06333015 is a clinical study titled "Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction". This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
What is the current status of trial NCT06333015?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 304 participants. The study started on 2024-08-07. Estimated completion is 2026-07.
What conditions does trial NCT06333015 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT06333015?
The interventions under investigation include: enVista Beyond EY (EDF) IOL (DEVICE), enVista MX60E monofocal IOL (DEVICE).
Who is sponsoring clinical trial NCT06333015?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06333015 being conducted?
This trial has 16 study locations across Alabama, California, Minnesota, Nebraska, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06333015's enrollment target sits among peer trials
304 18th of 83 higher than 66 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
RECRUITING · NA
-
Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery
RECRUITING · NA
-
Quatera 700 vs. Centurion
ACTIVE NOT RECRUITING · NA
-
Cataract Monitored Anesthesia Care (MAC) Feasibility Pilot Study
ACTIVE NOT RECRUITING · NA
-
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI